Proteasome inhibition as a therapeutic strategy for hematologic malignancies (Q36185620)

12 August 2017

1 reference

title

Proteasome inhibition as a therapeutic strategy for hematologic malignancies (English)

1 reference

12 August 2017

5

Kenneth C Anderson

1 reference

12 August 2017

4

Paul G Richardson

1 reference

12 August 2017

3

Teru Hideshima

1 reference

PubMed ID

16001954

12 August 2017

Constantine S Mitsiades

series ordinal

1

object named as

Constantine S Mitsiades

1 reference

12 August 2017

2

Nicholas Mitsiades

1 reference

12 August 2017

1 June 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

3

1 reference

12 August 2017

465-476

1 reference

The ubiquitin-proteasome proteolytic pathway

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Nobel Prizes. Gold medal from cellular trash

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Emerging roles of ubiquitin in transcription regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Structure and function of the 20S proteasome and of its regulatory complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Protein degradation by the proteasome and dissection of its in vivo importance with synthetic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

The proteasome, a novel protease regulated by multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Focus on multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Proteasome inhibition: a new strategy in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Preferential induction of apoptosis for primary human leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

XBP-1 Regulates a Subset of Endoplasmic Reticulum Resident Chaperone Genes in the Unfolded Protein Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

NF-kappaB in cancer: from innocent bystander to major culprit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Identification of genes modulated in multiple myeloma using genetically identical twin samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Role of interleukin 6 in the growth of myeloma-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Activation of the cell death program by inhibition of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Epoetin-induced autoimmune pure red cell aplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.465

21 January 2018

Identifiers

DOI

10.1586/14737140.5.3.465

1 reference

12 August 2017

1 reference

PubMed ID

16001954